In last trading session, Mereo Biopharma Group Plc ADR (NASDAQ:MREO) saw 2.86 million shares changing hands with its beta currently measuring 0.46. Company’s recent per share price level of $1.75 trading at $0.04 or 2.34% at ring of the bell on the day assigns it a market valuation of $278.25M. That closing price of MREO’s stock is at a discount of -186.86% from its 52-week high price of $5.02 and is indicating a premium of 10.29% from its 52-week low price of $1.57. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 6.45 million shares which gives us an average trading volume of 2.20 million if we extend that period to 3-months.
For Mereo Biopharma Group Plc ADR (MREO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.11. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.01 in the current quarter.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
Upright in the green during last session for gaining 2.34%, in the last five days MREO remained trading in the red while hitting it’s week-highest on Thursday, 07/10/25 when the stock touched $1.75 price level, adding 14.63% to its value on the day. Mereo Biopharma Group Plc ADR’s shares saw a change of -57.83% in year-to-date performance and have moved -40.48% in past 5-day. Mereo Biopharma Group Plc ADR (NASDAQ:MREO) showed a performance of -36.59% in past 30-days. Number of shares sold short was 7.96 million shares which calculate 6.64 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 65.0% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -185.71% in reaching the projected high whereas dropping to the targeted low would mean a loss of -185.71% for stock’s current value.
And 7 analysts are in estimates of company making revenue of 7.8M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 34.82% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 58.86% while estimates for its earnings growth in next 5 years are of 25.31%.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s Major holders
Insiders are in possession of 0.96% of company’s total shares while institution are holding 76.57 percent of that, with stock having share float percentage of 77.31%. Investors also watch the number of corporate investors in a company very closely, which is 76.57% institutions for Mereo Biopharma Group Plc ADR that are currently holding shares of the company. RUBRIC CAPITAL MANAGEMENT LP is the top institutional holder at MREO for having 15.31 million shares of worth $55.11 million. And as of 2024-06-30, it was holding 2.1506 of the company’s outstanding shares.
The second largest institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., which was holding about 11.79 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.6566 of outstanding shares, having a total worth of $42.45 million.
On the other hand, abrdn World Healthcare Fund and abrdn Life Sciences Investors are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 1.3 shares of worth $2.28 million or 0.82% of the total outstanding shares. The later fund manager was in possession of 812.05 shares on Mar 31, 2025 , making its stake of worth around $1.42 million in the company or a holder of 0.51% of company’s stock.
